Sun Pharmaceutical Industries has secured a significant legal victory in the United States, with the Third Circuit Court of Appeals affirming summary judgment in its favor regarding antitrust litigation over generic Lipitor (Atorvastatin). The appellate court's decision denies class certification for plaintiffs and brings the long-standing dispute substantially to a close.

The litigation centered on a 2008 patent settlement agreement between Sun Pharma and Pfizer. Plaintiffs alleged that this settlement unlawfully delayed the entry of generic competition for Lipitor into the US market, arguing that absent the agreement, the generic version would have launched earlier.

Legal outcome

The United States Court of Appeals for the Third Circuit upheld the order from the United States District Court. The lower court had previously granted summary judgment in its entirety to Sun Pharmaceutical Industries Limited and certain of its subsidiaries.

Key aspects of the appellate decision are summarised below:

This outcome represents a favorable development for the company, removing a material legal overhang associated with the case. The matter is now considered substantially closed, subject only to any further remedies available to plaintiffs under applicable law.

Regulatory disclosure

The company disclosed the update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sun Pharma has consistently disclosed the status of this matter in its financial statements throughout the duration of the litigation.

Sun Pharmaceutical Industries Limited has secured regulatory clearance from India’s premier stock exchanges to reclassify key members of its promoter group into the public category. The National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) issued no-objection letters dated August 06, 2026, approving the request submitted by the company on May 26, 2026. This move alters the shareholding structure classification for Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia, shifting them from the ‘Promoter Group’ to the ‘Public’ category in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The reclassification follows a series of prior intimations issued by Sun Pharmaceutical Industries Ltd on May 14, 2026, May 22, 2026, and May 26, 2026. The company notified stakeholders of its intent to seek this change, which is procedurally required when promoters wish to exit the promoter category or when their holding falls below specified thresholds, though the specific reason for this reclassification was not detailed in the exchange filings beyond the regulatory compliance aspect.

Reclassification Details

The no-objection letters from both exchanges confirm the approval for the following individuals:

The exchanges emphasized that Sun Pharmaceutical Industries Ltd must ensure compliance with subsequent relevant disclosures of material events related to this reclassification, as mandated by Regulation 31A of the SEBI Listing Regulations. Copies of the no-objection letters are available on the company’s website at www.sunpharma.com .

Regulatory Compliance

The intimation was issued under Regulation 30 and Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Anoop Anjanikumar Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Ltd, signed the disclosure. The registered office of the company is located at SPARC, Tandalja, Vadodara, Gujarat.

This reclassification impacts how the shareholding pattern is reported in future quarterly disclosures. Shares held by the named individuals will now be aggregated under the public category rather than the promoter group, potentially affecting metrics related to promoter pledge limits and public float calculations, although the immediate financial impact remains neutral as it is a structural classification change rather than a transactional event.